The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

A norovirus vaccine based on the mRNA technology that helped to defeat Covid will be trialled in the UK for the first time, ...

It is hoped a study will show the jab is effective against the highly infectious disease which puts the NHS under "huge ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...